In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Start-Up Previews, July-August 2012

Executive Summary

This Month's Profile Groups: Making The Business Of Drug Adherence An Easier Pill To Swallow, features profiles of HealthPrize Technologies, Pill Jogger, RxAnte and SentiCare. New Access Devices Create Gateway To Interventional Structural Heart Disease features profiles of Apica Cardiovascular, Entourage Medical and Inseal Medical. Plus these Start-Ups Across Health Care: CanDiag, CoolSpine, Genkyotex, MGI Medical, MitrAssist Medical, SA Ignite, Savara Pharmaceuticals and StnDrd Infusion.

You may also be interested in...



Making The Business Of Drug Adherence An Easier Pill To Swallow

Medication adherence is a big problem, and recent studies are bringing the actual costs and causes into sharper focus. At the same time, health care reforms such as electronic health records and prescriptions, as well as new incentives from the US government, have encouraged investors to tackle solutions to the problem. Questions remain about the impact of these reforms, but the companies profiled in this issue, HealthPrize Technologies, PillJogger, RxAnte and SentiCare, see an evolving climate in which their medication adherence technology solutions can turn into profitable businesses.

New Access Devices Create Gateway To Interventional Structural Heart Disease

Now that transcatheter heart valves have been implanted in thousands of humans, it’s becoming clear where the problems lie. Vascular and bleeding complications, stroke and paravalvular leaks are the most troubling consequences. Most of the focus has been on improving the valves and the delivery systems, but now innovators are looking at the issue of access – the particular ways by which therapeutic devices enter the heart – and how it can be changed to improve outcomes. In this issue we profile Apica Cardiovascular, Entourage Medical and Inseal Medical.

Inseal Medical Ltd.

New minimally invasive interventions for structural heart disease use ever larger devices, creating challenges for transfemoral access site management. While the current state of the art is trying to transform surgical practices into interventional ones, Inseal Medical has a large-bore vascular access closure device that works the way interventional cardiologists do.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

MT065510

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel